IgG Antibody Response Elicited by a Fully Synthetic Two-Component Carbohydrate-Based Cancer Vaccine Candidate with α-Galactosylceramide as Built-in Adjuvant,Organic Letters

当前位置： X-MOL 学术 › Org. Lett. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

IgG Antibody Response Elicited by a Fully Synthetic Two-Component Carbohydrate-Based Cancer Vaccine Candidate with α-Galactosylceramide as Built-in Adjuvant
Organic Letters ( IF 4.9 ) Pub Date : 2017-01-25 00:00:00 , DOI: 10.1021/acs.orglett.6b03591
Xu-Guang Yin ₁ , Xiang-Zhao Chen ₁ , Wen-Mei Sun ₁ , Xiao-Shan Geng ₁ , Xiao-Kang Zhang ₁ , Jian Wang ₁ , Pan-Pan Ji ₂ , Zhong-Yin Zhou ₂ , Dong Jae Baek ₃ , Guang-Fu Yang ₁ , Zheng Liu ₁ , Jun Guo ₁

Affiliation

A fully synthetic self-adjuvanting cancer vaccine candidate was constructed through covalent conjugation of invariant natural killer T (iNKT) cell ligand α-galactosylceramide (αGalCer) with sialyl Tn (STn), a representative tumor-associated carbohydrate antigen (TACA). This two-component vaccine STn-αGalCer is devoid of antigenic peptide, featuring the well-defined structure with high simplicity. STn-αGalCer showed remarkable efficacy in inducing antibody class switching from IgM to STn-specific IgG. Subtypes of IgG antibody were primarily IgG1 and IgG3.

中文翻译：

含α-半乳糖苷神经酰胺作为内在佐剂的完全基于合成的两组分糖基癌症候选疫苗可激发IgG抗体应答

通过将不变的自然杀伤T（i NKT）细胞配体α-半乳糖基神经酰胺（αGalCer）与代表肿瘤相关的碳水化合物抗原（TACA）唾液酸Tn（STn）共价偶联，构建了完全合成的自佐剂性癌症疫苗候选物。这种两组分疫苗STn-αGalCer不含抗原肽，具有结构明确，高度简单的特点。STn-αGalCer在诱导从IgM到STn特异性IgG的抗体类别转换中显示出显着的功效。IgG抗体的亚型主要是IgG1和IgG3。

更新日期：2017-01-25

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南